SCHEMBL5459817

SCHEMBL5459817

CC(=O)Oc1ccc2c(C(N)=O)c(NC(=O)C3CC3)sc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 2/20 0.44
FLT3 P36888 1/20 0.43
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
MAPK10 P53779 2/20 0.41
DYRK1A Q13627 1/20 0.40
MAPK1 P28482 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
PRNP P04156 1/20 0.39
TSHR P16473 1/20 0.39
PPARG P37231 1/20 0.39
HTT P42858 1/20 0.39
NCOA2 Q15596 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TNIK Q9UKE5 1/20 0.39
GFER P55789 1/20 0.38
CA2 P00918 2/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450710 0.89 MAPK10 (0.52) MAPTKDM4EFLT3AURKAAURKB
SCHEMBL5451020 0.86 ABL1 (0.49) MAPTKDM4EHSD17B10FLT3AURKA
SCHEMBL5451379 0.86 MEN1 (0.40) MAPTKDM4EHSD17B10FLT3AURKA
SCHEMBL5466117 0.83 FLT3 (0.48) MAPTFLT3AURKAAURKBMAPK10
SCHEMBL5456020 0.83 MAPT (0.41) MAPTKDM4EHSD17B10FLT3AURKA
SCHEMBL5449196 0.83 ABL1 (0.50) MAPTFLT3AURKAAURKBMAPK10
SCHEMBL5460935 0.82 MAPT (0.42) MAPTFLT3AURKAAURKBMAPK10
SCHEMBL5454161 0.82 FLT3 (0.41) MAPTFLT3AURKAAURKBMAPK10
SCHEMBL17611413 0.81 FLT3 (0.42) MAPTKDM4EHSD17B10FLT3AURKA
SCHEMBL5450964 0.81 FLT3 (0.48) MAPTFLT3AURKAAURKBMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885KDM4E 3417/4885HSD17B10 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.